http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Jun 2026 08:00:09 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Board+Changes/Eikon+Therapeutics+appoints+Ma.+Fatima+Francisco+to+board+of+directors/26614460.html <p>Eikon Therapeutics, Inc. (NASDAQ: EIKN) announced the appointment of Ma. Fatima Francisco as an independent director to its board of directors, effective June 15, 2026. Francisco will also serve on the board's compensation committee.</p> <p>Francisco previously served as Chief Executive Officer of Baby, Feminine and Family Care at The Procter & Gamble Company, where she led one of the company's largest global business units. During her more than 35-year career at Procter & Gamble, she held leadership positions across marketing, innovation, commercial operations and general management.</p> <p>Francisco currently serves on the boards of directors of HP Inc. and Nestle S.A., and previously http://www.streetinsider.com/Board+Changes/Eikon+Therapeutics+appoints+Ma.+Fatima+Francisco+to+board+of+directors/26614460.html Mon, 08 Jun 2026 08:00:09 -0400 EIKN http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Announces+the+Appointment+of+Ma.+Fatima+D.+Francisco+to+its+Board+of+Directors/26614434.html <p align="left">MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ma. Fatima ("Fama") D. Francisco as an independent director to Eikon’s Board of Directors, effective June 15, 2026. Ms. Francisco will also serve on the Compensation Committee of the Board.</p> <p align="left">"Fama brings a remarkable record of leadership, innovation and talent development from one of the world's most successful global enterprises," said Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Announces+the+Appointment+of+Ma.+Fatima+D.+Francisco+to+its+Board+of+Directors/26614434.html Mon, 08 Jun 2026 08:00:00 -0400 EIKN http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Announces+the+Appointment+of+Ma.+Fatima+D.+Francisco+to+its+Board+of+Directors/26614434.html <p align="left">MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ma. Fatima ("Fama") D. Francisco as an independent director to Eikon’s Board of Directors, effective June 15, 2026. Ms. Francisco will also serve on the Compensation Committee of the Board.</p> <p align="left">"Fama brings a remarkable record of leadership, innovation and talent development from one of the world's most successful global enterprises," said Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Announces+the+Appointment+of+Ma.+Fatima+D.+Francisco+to+its+Board+of+Directors/26614434.html Mon, 08 Jun 2026 08:00:00 -0400 EIKN http://www.streetinsider.com/Analyst+Comments/Eikon+Therapeutics+%28EIKN%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26587437.html <p>Cantor Fitzgerald analyst Imogen Mansfield reiterated an Overweight rating on Eikon Therapeutics Inc. (NASDAQ: EIKN).</p><p>The analyst commented, "We think EIKN's PARP1 inhibitors have best-in-class potential and could meaningfully grow the size of the "PARP pie," offering earlier-line combinability and expansion into BRCAwt patients. We estimate product launch for EIK1003/4 in 2031 with >$1.5B peak sales across indications, and continue to assume a 60% POS for this program. We see EIK1001 as a high risk/high reward opportunity. Data from early clinical studies and the Ph2 NSCLC cohort provide signs of encouragement, but conclusive evidence of superiority over control arms (pembro/chemo in http://www.streetinsider.com/Analyst+Comments/Eikon+Therapeutics+%28EIKN%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26587437.html Tue, 02 Jun 2026 07:29:26 -0400 EIKN http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Corporate+News/Eikon+Therapeutics+to+present+six+abstracts+at+2026+ASCO+meeting/26536639.html <p>Eikon Therapeutics, Inc. (NASDAQ: EIKN) announced that six abstracts from its clinical programs will be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago starting May 29, 2026.</p><p>The presentations will cover data from three drug candidates in the company's oncology pipeline. Three abstracts will focus on EIK1001, a TLR7 and TLR8 dual-agonist being tested in non-small cell lung cancer and advanced melanoma trials. The presentations include results from the Phase 2 TeLuRide-005 trial combining EIK1001 with standard first-line therapy in stage 4 non-small cell lung cancer, and data from two additional studies evaluating the drug in http://www.streetinsider.com/Corporate+News/Eikon+Therapeutics+to+present+six+abstracts+at+2026+ASCO+meeting/26536639.html Thu, 21 May 2026 17:05:25 -0400 EIKN http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Announces+Availability+of+Six+Abstracts+for+Presentation+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26536613.html <ul><li><em>Presentations to cover progress across Eikon’s most advanced clinical-stage programs</em></li><li><em>Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer (“NSCLC”), EIK1003, as a monotherapy or in combination in the treatment of patients with breast, ovarian, prostate, or pancreatic cancer, and EIK1005, which is designed to improve treatment of patients whose tumors demonstrate certain DNA replication abnormalities.</em></li></ul> <p>MILLBRAE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Announces+Availability+of+Six+Abstracts+for+Presentation+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26536613.html Thu, 21 May 2026 17:05:00 -0400 EIKN http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Announces+Availability+of+Six+Abstracts+for+Presentation+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26536613.html <ul><li><em>Presentations to cover progress across Eikon’s most advanced clinical-stage programs</em></li><li><em>Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer (“NSCLC”), EIK1003, as a monotherapy or in combination in the treatment of patients with breast, ovarian, prostate, or pancreatic cancer, and EIK1005, which is designed to improve treatment of patients whose tumors demonstrate certain DNA replication abnormalities.</em></li></ul> <p>MILLBRAE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Announces+Availability+of+Six+Abstracts+for+Presentation+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26536613.html Thu, 21 May 2026 17:05:00 -0400 EIKN http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468